RNF168 Antibody


Catalog No: #24885



Orders: order@signalwayantibody.com Support: tech@signalwayantibody.com

| Description | Support: tech@signalwayantibody.com |
|-----------------------|--|
| Product Name | RNF168 Antibody |
| Host Species | Rabbit |
| Clonality | Polyclonal |
| Purification | Affinity chromatography purified via peptide column |
| Applications | ELISA WB |
| Species Reactivity | Hu Ms |
| Immunogen Type | Peptide |
| Immunogen Description | Raised against an 18 amino acid peptide from near the carboxy terminus of human RNF168. |
| Target Name | RNF168 |
| Other Names | RING finger protein 168 |
| Accession No. | NP_689830 |
| Concentration | 1mg/ml |
| Formulation | Supplied in PBS containing 0.02% sodium azide. |
| Storage | Can be stored at -20°C, stable for one year. As with all antibodies care should be taken to avoid repeated |
| | freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures. |

Images



Western blot analysis of RNF168 in human brain tissue lysate with RNF168 antibody at 1 ug/mL.

Background

RNF168 was identified as a chromatin-associated RING finger protein that acts as a ubiquitin ligase both in vitro and in vivo. RNF168 targets histones H2A and H2AX, but not H2B, forming K63 polyubiquitin chains. Upon formation of DNA double strand breaks, RNF168 is recruited to the site of DNA damage where it co-localizes with gammaH2AX and 53BP1 in an RNF8-dependent manner. This localization of RNF168 increases the local concentration of ubiquinated proteins to the threshold required for retention of the proteins 53BP1 and BRCA1, facilitating the downstream signaling cascade. Thus, RNF168 defines a new pathway demonstrating a functional cooperation between E3 ligases in genome maintenance. At least three isoforms of RNF168 are known to exist.

| Note: This product is for in vitro research use only and is not intended for use in humans or animals. | | | |
|--|--|--|--|
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |